Background: Cardiovascular effects of alcohol consumption may be influenced by both pro-and anti-inflammatory mechanisms. We previously showed that chronic alcohol consumption increased blood pressure (BP), oxidative stress, and 20-hydroxyeicosatetraenoic acid (20-HETE), a vasoconstrictor and pro-inflammatory eicosanoid synthesized by cytochrome P450 (CYP450) enzymes from arachidonic acid. This study in men examined the effect of consuming red wine (RW) on BP in relation to changes in 20-HETE, oxidative stress (F 2 -isoprostanes), markers of inflammation, anti-inflammatory CYP450 epoxyeicosatrienoic acids (EETs), and specialized pro-resolving mediators of inflammation (SPMs) derived from eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).
M ODERATE-to-high alcohol consumption is a major contributor to elevated blood pressure (BP) (Klatsky, 2015) . However, the mechanisms underlying this association are not fully understood. In a cross-sectional study of 69 treated hypertensives, we showed a significant positive correlation between usual alcohol intake and urinary 20-hydroxyeicosatetraenoic acid (20-HETE) excretion (Ward et al., 2005) . 20-HETE is a potent vasoconstrictor eicosanoid derived from cytochrome P450 (CYP450) x-hydroxylase metabolism of arachidonic acid (AA). AA is also metabolized by CYP450 epoxygenases producing 4 epoxyeicosatrienoic acids (EETs) (5, 8, 11, and 14, (Roman, 2002) . The EETs, that are vasodilatory and anti-inflammatory, are metabolized to their inactive dihydroxyeicosatrienoic acids (DHETs) by soluble epoxide hydrolase (Fig. 1) . We subsequently showed that reducing beer intake by~60 g alcohol/d for 4 weeks in 16 healthy males substantially reduced 24-h urinary 20-HETE, raising the possibility that altered 20-HETE synthesis may constitute an important mechanism for the development of alcohol-related hypertension (Barden et al., 2007) . In the same study, reducing beer intake significantly reduced plasma total F 2 -isoprostanes (Barden et al., 2007) that are markers of in vivo oxidative stress formed via nonenzymatic free radical attack on AA (Fig. 1) . Imhof and colleagues (2001) showed a U-shaped relationship between alcohol consumption and markers of inflammation. In a population study, nondrinkers and heavy drinkers had higher C-reactive protein (CRP) concentrations than moderate drinkers (Imhof et al., 2001) . The effect of alcohol to increase 20-HETE may affect vascular inflammation. 20-HETE can activate NF-jB and the MAPK/ERK signaling pathways, inducing pro-inflammatory cytokines and transforming endothelium to an inflammatory phenotype (Hoopes et al., 2015; Ishizuka et al., 2008) . 20-HETE has been implicated in the vascular inflammation associated with ischemia/reperfusion injury (Hoff et al., 2011) and cerebrovascular inflammation in the spontaneously hypertensive rat (Toth et al., 2013) .
Alcohol also has the potential to alter inflammation resolution, a process that is driven by specialized pro-resolving mediators of inflammation (SPMs). The SPMs include lipoxins from AA and resolvins, protectins, and maresins derived from eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). SPMs have been shown to halt neutrophil infiltration, and enhance macrophage uptake of apoptotic cells and debris, promoting a return to homeostasis. (Barden et al., 2016; Serhan et al., 2015a) . Alcohol could affect synthesis of SPMs by affecting the availability of fatty acid substrates (Kim et al., 2007) and altering the activity of key enzymes involved in SPM synthesis, namely CYP450 (Salmela et al., 1998) , COX-2 (Knapp and Crews, 1999) , and 5-lipoxygenase (Wheelan and Murphy, 1997) (Fig. 1) .
This study aimed to examine the effect of consuming red wine (RW) on BP in moderate to heavy drinking, but otherwise healthy men, in relation to changes in 20-HETE and EETs, oxidative stress, markers of inflammation, and SPM. We hypothesized that chronic alcohol consumption would increase BP, 20-HETE, markers of inflammation, and oxidative stress and attenuate SPM.
MATERIALS AND METHODS

Recruitment and Study Design
Study Participants. Healthy males aged 20 to 65 years, who were regular drinkers consuming between 40 and 100 g alcohol/ d, were sought by advertisement from the general population in Perth, Western Australia between 2008 and 2009. Women were excluded from the study because the protocol required that a relatively high daily dose of alcohol be consumed. Participants had a body mass index (BMI) <30 kg/m 2 and no history of liver disease, cardiovascular disease, diabetes mellitus, hypertension, or dyslipidemia. They were nonsmokers, not taking medication including aspirin or nonsteroidal anti-inflammatory drugs. A questionnaire assessed previous alcohol consumption detailing the type of beverage (beer, wine, and spirits) frequency of consumption (every day, 5 to 7 times/wk, 1 to 4 times/wk, 1 to 4 times/month, <1 time/month) and the duration of consumption (<1 year, 1 to 2 years, 2 to 5 years, and >5 years). At a screening visit, 6 BP readings were obtained at 1-minute intervals, after 5-minute seated rest, using a Dinamap Pro 200 (GE Medical Systems, Tampa, FL), and an ECG recording was obtained. Blood was collected for measurement of glucose, lipids, and liver function. A medical examination by a physician determined each volunteer's suitability for the study. The physical examination excluded volunteers that had any pathology (neural, hepatic, or cardiac) that might characterize them as alcoholics, but no formal questionnaire was administered to assess alcoholism. The level of alcohol exposure during the study was at the upper limit for men defined by National Health and Medical Research Council of Australia guidelines at the time of the study.
Study Design. During a 2-week run-in period, participants were asked to abstain from drinking alcohol. Baseline measurements were then obtained, and they entered a 3-period open-label Fig. 1 . A schematic overview of bioactive eicosanoids from arachidonic acid (AA), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA) involved in vascular function and inflammation resolution. AA is metabolized by cyclooxygenase (COX-1 and 2) forming prostaglandins (PGs) and thromboxane A 2 (TXA 2 ); lipoxygenases (5-LOX) to leukotriene B 4 (LTB 4 ), and (5-LOX and 15-LOX) to lipoxins (LXA 4 and LXB 4 ); cytochrome P450 (CYP450) to 20-hydroxyeicosatetraenoic acid (20-HETE) and epoxyeicosatrienoic acids (EETs). EETs are inactivated by soluble epoxide hydrolase (sEH) forming dihydroxyeicosatrienoic acids (DHETs). AA also undergoes nonenzymatic free radical oxidation to F 2 -isoprostanes. EPA is metabolized by COX-2/ CYP450 to 18-HEPE with further metabolism by 5-LOX and 15-LOX forming E-series resolvins (RvE1 to RvE3). DHA metabolism by COX-2/15-LOX results in formation 17-HDHA that is further metabolized to PD1, 10S,17S-DHDHA, and D-series resolvins. DHA metabolism by 12-LOX leads to the maresins (MaR-1 and 14-HDHA). The eicosanoids in black boxes denote those measured in this study. crossover trial. Each period was 4 weeks in duration with no washout between interventions. During the 3 study periods, they consumed either RW (375 ml/d, 41 g alcohol) or the equivalent volume of dealcoholized red wine (DRW) or water in an unblinded study. They were instructed to drink the beverages provided with their evening meal and to refrain from drinking any other alcohol for the 12 weeks of the study. They were allocated to each study period sequence via block randomization using computer-generated random numbers, devised by the statistician. The RW and DRW were supplied by Orlando Wines, South Australia, and had an alcohol and polyphenol content of~14% and 2,378 mg/l and 0.6% and 2,284 mg/l, respectively. Volunteers were asked to maintain their usual diet and exercise throughout the study with emphasis not to alter consumption of tea and coffee, a rich source of polyphenols. Researchers entering BP and biochemical data or performing laboratory analyses were blinded to the treatment sequences.
The study compared effects of RW with DRW and water on CYP450 eicosanoids and BP (primary outcomes) and F 2 -isoprostanes and SPM (secondary outcomes). The trial was conducted according to the Declaration of Helsinki guidelines and approved by the University of Western Australia Human Research Ethics Committee. Written informed consent was obtained from all participants. The trial was registered with the Australian New Zealand Clinical Trials Registry (ANZCTR), ACTRN12608000207314.
BP Monitoring. Ambulatory BP was measured after the 2-week run-in period (baseline) and after each of the 4-week treatment periods. An ambulatory BP monitor (Spacelabs 90207; Spacelabs Healthcare, Issaquah, WA) was fitted to the nondominant arm by a trained researcher who explained its use to the participants. BP and heart rate were monitored over 24 hours at 20-minute intervals while awake and at 30-minute intervals while asleep. Volunteers were instructed to continue their usual daily activities, avoid any vigorous exercise, and to keep a diary documenting when they were awake or asleep. Measurements showing an error code or those with a pulse pressure <20 mm Hg were excluded from the analysis. BP measurements were considered complete if >80% of the recordings were valid. BP readings from each subject were aggregated to calculate average hourly results.
Measurement of Compliance and Lifestyle Change. A 7-day retrospective alcohol diary was completed each week to monitor alcohol intake. A fasting BP was provided at the end of the 2-week run-in period and the end of each study period for c-glutamyl transpeptidase as a biomarker of change in alcohol intake, and total cholesterol, triglycerides, high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C). Volunteers were advised not to change their usual dietary habits or level of physical activity throughout the study. Questionnaires were administered throughout the study to evaluate changes in diet including major food groups, tea, coffee, and alcohol consumption, as well as any changes in the type and amount of physical activity. Body weight was monitored throughout the study. Urinary 4-O-methylgallic acid was measured as a biomarker of RW polyphenol intake (AbuAmsha et al., 1996) . Biochemical Analyses. A fasted blood sample and 24-hour urine collection were collected at baseline, 4, 8, and 12 weeks. Serum samples were analyzed by PathWest Laboratories, Royal Perth Hospital, using the Hitachi 917 Biochemical Analyser (Hitachi Limited, Tokyo, Japan). c-Glutamyl transpeptidase was measured with a Roche kit (D-68298; Roche Diagnostics GmbH, Mannheim, Germany). HDL-C was measured with the Boehringer Mannheim kit (Boehringer Mannheim GmbH Diagnostica, Copenhagen, Denmark). LDL-C was calculated using the Friedewald formula (Friedewald et al., 1972) . High-sensitivity-CRP (hs-CRP) was measured by nephelometry at PathWest Laboratories. Aliquots from 24-hour urine collections stored at À80°C were assayed for 4-Omethylgallic acid in our laboratory by gas chromatography-mass spectrometry (GCMS) (Caccetta et al., 2000) . All samples from each subject were assayed in the 1 batch.
Measurement CYP450 Eicosanoids and F 2 -Isoprostanes. Plasma and urinary 20-HETE (Barden et al., 2013) , plasma total EETs and DHETs (Barden et al., 2013) , and plasma and urinary F 2 -isoprostanes (Tsai et al., 2009) were measured in our laboratory by GCMS as previously described, with the technician blinded to the allocation sequence of the study participants.
Measurement of Plasma SPMs. Venous blood (10 ml) from the antecubital fossa was collected on ice into EDTA (2.5 mM), butylated hydroxytoluene (0.18 mM), and reduced glutathione (3.3 mM), centrifuged at 4°C, and the plasma was stored at À80°C until analysis. SPMs were measured in plasma (1 ml) using liquid chromatography-tandem mass spectrometry as previously described (Barden et al., 2014; Mas et al., 2012) . The retention time of standards, their mass spectrum and parent and product ions, and collision energy were used to identify individual SPM. Standards of SPMs derived from EPA were 18R/S-hydroxy-eicosapentaenoic acid (18R/S-HEPE), resolvin E1 (RvE1), resolvin E2 (RvE2), resolvin E3 (RvE3), and 18R-resolvin E3 (18R-RvE3). Standards of SPMs derived from DHA were 17S-hydroxy-docosahexaenoic acid (17S-HDHA), resolvin D1 (RvD1), 17R-resolvin D1 (17R-RvD1), resolvin D2 (RvD2), 10S,17S-dihydroxy-docosahexaenoic acid (10S,17S-DHDHA), (AE)14-hydroxy-docosahexaenoic acid (14R/S-HDHA), and maresin-1 (MaR-1), and protectin-1 (PD1).
Statistical Analysis
An initial power analysis on the primary outcomes, urinary 20-HETE, and BP, determined 20 to 25 participants would give 80% power to detect a 20% difference in urinary 20-HETE and a 5 mm Hg difference in systolic BP (SBP) at a significance level of p < 0.05. The study was powered to detect the secondary outcome differences of 20% for plasma F 2 -isoprostanes and 18-HEPE based upon repeated-measures analysis of variance.
In the final data analysis, changes in SBP, diastolic BP (DBP), and heart rate, plasma and urine CYP450 eicosanoids and F 2 -isoprostanes, and plasma SPMs were examined using linear mixed model analysis adjusted for baseline measurements and compared for each beverage using linear mixed models with restricted maximum-likelihood estimation. The changes to the initial analysis plan were made because of the gain in statistical power of mixed/multilevel analysis. A covariate was entered into each of the regression analyses to test for the effects of the randomization order on each of the outcome variables. The relationship between urinary 20-HETE and plasma 18-HEPE was examined using a linear mixed model that adjusted for baseline measurements and used an interaction term to test for differences in the slope of relationship attributed to each beverage.
RESULTS
Seventy-one men were phone screened, and 30 attended the research unit for anthropometry, BP measurement, biochemical screening, and a physical examination. Twenty-two men who were moderate-to-high alcohol drinkers commenced and completed the study (Fig. S1) . Eleven of the men reported the duration of their current alcohol consumption was <5 years and eleven ≥5 years. They were middle aged and slightly overweight, but otherwise healthy, with lipids and glucose within the normal range for adults (Table 1) . Eighty-six percent were prehypertensive (SBP between 120 mm Hg and 139 mm Hg). Compliance with alcohol consumption during the study assessed by alcohol diaries and cGT was excellent. Alcohol intake assessed from alcohol diaries was 45.4 g/d after drinking RW, compared with 7.9 g/d after DRW and 4.9 g/d after water. cGT a marker of alcohol intake was significantly elevated after drinking RW (33.1 AE 4.1 U/l, p < 0.05) compared with DRW (28.7 AE 4.1 U/l) and water (29.0 AE 4.0 U/l). Urinary 4-O-methylgallic acid, as a measure of compliance with consumption of RW and DRW, was similar during the RW (1,821 AE 455 lg/24 h) and DRW (1,680 AE 346 lg/24 h) treatment periods and significantly elevated compared with the period of water consumption (672 AE 234 lg/24 h, p < 0.01).
Total cholesterol, LDL-C, and triglycerides were not differentially affected by consumption of any of the beverages (data not shown). In contrast, HDL-C was significantly elevated after RW (1.4 AE 0.1 mmol/l, p < 0.05) compared with DRW (1.2 AE 0.1 mmol/l) and water (1.2 AE 0.1 mmol/ l). Body weight did not change throughout the study, and there were no changes in diet or exercise and no reported side effects of any of the treatments.
BP and Heart Rate
After adjusting for baseline BP, drinking RW for 4 weeks increased 24-hour ambulatory BP compared with DRW and water (SBP +1.4 AE 0.5 mm Hg, p = 0.003 and DBP +0.8 AE 0.4 mm Hg, p = 0.032) (Table 2, Fig. 2) . This was mainly due to an increase in BP during awake hours (SBP +1.6 AE 0.6 mm Hg, p = 0.003 and DBP +1.0 AE 0.4 mm Hg, p = 0.02) ( Table 2 , Fig. 2 ). Heart rate was increased over the 24 hours after RW compared with DRW (+4.8 AE 0.4 beats/min, p < 0.0001) after adjusting for heart rate at baseline. Heart rate was increased by 6.9 AE 0.6 beats/min, p = 0.001 when asleep and by 3.8 AE 0.3 beats/min, p = 0.001 while awake (Table 2, Fig. 2 ). After 4 weeks drinking DRW, 24-hour heart rate was reduced compared with the period of drinking water (À2.0 AE 0.4 beats/min, p = 0.001) and was lower while awake (À2.1 AE 0.6 beats/ min, p = 0.001) and while asleep (À1.8 AE 0.7 beats/min, p = 0.006) (Table 2, Fig. 2 ).
CYP450 Eicosanoids
Urinary 20-HETE was higher after consuming RW when compared with DRW (p < 0.0001) and water (p = 0.0003) (Fig. 3A, Table S1 ). Plasma 20-HETE was higher after RW compared with DRW (p = 0.049) (Fig. 3B, Table S1 ), but EETs and DHETS were not significantly different across the 3 treatment periods (Fig. 3C,D , Table S1 ). The effect of 4 weeks consumption of DRW on urinary 20-HETE and plasma 20-HETE, EETs, and DHETs was not different from drinking water (Fig. 3A-D) . 
Plasma and Urinary F 2 -Isoprostanes
Plasma F 2 -isoprostanes were elevated after consumption of RW compared with DRW (p < 0.0001) and water (p < 0.0001) (Fig. 3E, Table S1 ). Urinary F 2 -isoprostanes were not different across the 3 treatment periods (Fig. 3F , Table S1 ). The effect of 4 weeks consumption of DRW on plasma and urinary F 2 -isoprostanes was not different from drinking water.
Markers of Inflammation and Resolution of Inflammation
hs-CRP was not altered by any of the beverages and was 1.36 AE 0.30 mg/l at baseline, 1.14 AE 0.30 mg/l after water; 1.12 AE 0.30 mg/l after DRW; and 1.27 AE 0.30 mg/l after RW. In contrast, several SPMs were significantly affected by consumption of RW. Plasma 18-HEPE derived from EPA, and RvD1 and 17R-RvD1 from DHA, was significantly elevated (p < 0.05) after consumption of RW compared with DRW and water (Fig. 4, Table S1 ). 17-HDHA and 14-HDHA were not significantly affected by the different beverages and were, respectively, 537 AE 40 pmol/l and 4,641 AE 697 pmol/l after water, 528 AE 44 pmol/l and 3,706 AE 755 pmol/l after DRW, and 534 AE 44 pmol/l and 3,800 AE 737 pmol/l after RW. The E-series resolvins, PD1, 10S, 17S-DHDHA, and MaR-1 were not detected.
Relationship Between 20-HETE and SPMs
We examined the relationship between 20-HETE and SPMs because CYP450 enzymes are common to the biosynthesis of both families of compounds. Urinary 20-HETE was positively correlated with plasma 18-HEPE (q = 0.32, p = 0.004). Using a linear mixed model analysis, we examined the linear relationship between urinary 20-HETE and 18-HEPE while consuming different beverages (Table S2) . After adjusting for 18-HEPE at baseline, the slope of the relationship between urinary 20-HETE and 18-HEPE was significantly increased when drinking RW compared with water (p = 0.008). The relationship between DRW and water was not different (Fig. S2 ). There were no significant relationships between urinary 20-HETE and plasma RvD1 or 17-RvD1 that were affected by drinking different beverages.
DISCUSSION
This study in men has shown for the first time that consuming 375 ml of RW/d for 4 weeks increases BP, vasoconstrictor CYP450 eicosanoids (20-HETE), and oxidative stress (F 2 -isoprostanes), while simultaneously increasing SPMs that mediate resolution of inflammation. The effects appear to be due to the alcohol content of the RW, as effects attributed to consumption of polyphenols in DRW were not different from those when drinking water. The study demonstrates that moderate-to-high alcohol consumption in men affects eicosanoid synthesis in a complex manner, suggesting that these pathways are important mechanisms relevant to the effects of alcohol on BP and inflammatory responses.
The study showed a modest increase in 24-hour SBP and DBP after 4 weeks of drinking alcohol provided as RW. The increase was mainly due to an increase in BP while awake. The magnitude of the BP increase after RW was comparable to our previous study where a similar quantity of alcohol was provided as beer or RW (Zilkens et al., 2005) . The 1.4 mm Hg increase in 24-hour SBP after drinking RW may have significant relevance at a population , markers of oxidative stress plasma F 2 -isoprostanes (E), and urinary F 2 -isoprostanes (F) after consuming water (white bars), DRW (gray bars), or RW (black bars). Urinary and plasma 20-HETE were higher after RW compared with DRW, †p < 0.01,*p < 0.05. Plasma F 2 -isoprostanes were higher after RW compared with DRW and water †p < 0.001.
level. The Atherosclerosis Risk in Communities Study suggests that a population-wide strategy to reduce SBP by 1 mm Hg would result in substantial reductions in heart failure, stroke, and coronary heart disease (Hardy et al., 2015) . Therefore, public health campaigns to reduce alcohol intake should be promoted to reduce cardiovascular disease at a population level.
There were no independent effects of RW polyphenols per se (DRW) on SBP or DBP. This finding agrees with our previous studies in normotensive men (Zilkens et al., 2005) , premenopausal women (Mori et al., 2015) , and patients with type 2 diabetes as well as those in patients with high-normal BP and hypertension (Botden et al., 2012) . However, the results are in contrast with the study of Chiva-Blanch and colleagues (2012) who showed a similar quantity of polyphenols lowered BP in diabetics or individuals with 3 or more cardiovascular risk factors. This could be due to the fact that our studies (Mori et al., 2015 Zilkens et al., 2005) and that of Botden and colleagues (2012) measured 24-hour ambulatory BP, whereas the study of Chiva-Blanch and colleagues (2012) measured BP 3 times at 5-minute intervals at the end of each intervention.
Our study showed an increase in 24-hour heart rate during RW consumption that was similar to that previously reported by us in normotensive men (Zilkens et al., 2005) . There was also a reduction in 24-hour heart rate during consumption of DRW. The latter finding agrees with a metaanalysis that showed grape seed polyphenols reduced heart rate (Feringa et al., 2011) . It is noteworthy that the grape polyphenol intake of the DRW (856 mg/d) in our study was within range of studies included in the meta-analysis (range 150 to 2,000 mg/d).
There was a significant increase in the vasoconstrictor CYP450 eicosanoid 20-HETE in plasma and urine after drinking RW. Levels of total plasma EETs, vasodilators formed by CYP450 epoxygenases, and their soluble epoxide hydroxylase metabolites (DHETs) (Fig. 1) , were unaffected by consumption of RW. The increase in plasma 20-HETE but not EETs agrees with our previous finding following the acute ingestion of RW (Barden et al., 2013) . 20-HETE has been shown to play a role in inflammation by stimulating the synthesis of pro-inflammatory mediators (Ishizuka et al., 2008) .
We observed effects of RW on oxidative stress with an increase in plasma but not urine F 2 -isoprostanes, a finding that is consistent with our study in moderate-to-heavy drinkers where alcohol was consumed as beer (Barden et al., 2007) .
The increase in oxidative stress and 20-HETE are potential mechanisms contributing to the increase in BP after alcohol. Future studies examining sodium balance during alcohol consumption are needed to determine whether the natriuretic actions of 20-HETE in the kidney (Roman, 2002) vasoconstrictor effects thereby attenuating the increase in BP after alcohol.
We did not observe any differential effect of RW on the inflammatory marker hs-CRP, an acute phase reactant produced in the liver in response to inflammation. This agrees with a meta-analysis that pooled the results of 5 intervention studies and found no significant effect of alcohol on CRP levels (Brien et al., 2011) . This is the first intervention in humans reporting an increase in plasma SPMs without n-3 supplementation. We found that RW increased 18-HEPE that is formed by the actions of CYP450 and/or COX2 on EPA. We also found that RvD1 and 17R-RvD1 that derive from DHA were significantly increased. These findings are significant given that the SPMs increased by RW are all known to be biologically active (Serhan et al., 2015b) . 18-HEPE has been shown to reduce maladaptive cardiac remodeling in mice (Endo et al., 2014) . RvD1 and 17R-RvD1 have been implicated in the control of inflammatory pain (Serhan et al., 2015a) . In experimental models, RvD1 has been shown to accelerate wound healing in diabetes, prevent colitis, and inhibit kidney fibrosis (Barden et al., 2016) , as well as improving ventricular function following myocardial infarction (Kain et al., 2015) .
We had hypothesized alcohol could affect synthesis of SPMs by altering the activity of key enzymes involved in SPM synthesis. In regression analysis, we found that the slope of the linear association between urinary 20-HETE and plasma 18-HEPE was significantly greater when drinking RW. Alcohol is known to stimulate the CYP450 2E1 enzyme (Pelkonen et al., 1998) ; therefore, our results could suggest that other CYP450 enzymes involved in the synthesis of both 20-HETE and 18-HEPE are also stimulated by the alcohol in RW. This is supported by our finding that there was no significant relationship between 20-HETE and RvD1 or 17R-RvD1, as both of these SPM are formed independently of CYP450 enzymes. It is possible that the increase in RvD1 and 17R-RvD1 could be due to an effect of alcohol to stimulate 5-lipoxygenase (Guo et al., 2011) .
The strengths of this study are that it examined the independent effects of alcohol and polyphenols on BP and a comprehensive range of CYP450 eicosanoids, markers of oxidative stress and inflammation, and mediators of inflammation resolution that may be relevant to the effect of alcohol on cardiovascular disease risk. The limitations of the study are that the study population was confined to men who were regular drinkers with moderate-to-high alcohol intake. Therefore, our results cannot be extrapolated to males consuming lower amounts of alcohol or to female drinkers.
This study has shown that moderate-to-high alcohol consumption as RW for 4 weeks increases BP, 20-HETE, and oxidative stress, while also increasing a number of SPM associated with the resolution of inflammation. These paradoxical findings require further studies to elucidate whether different CYP450 enzymes are involved, and whether the findings can be replicated in females. The implication of these findings for the effects of alcohol on BP and coronary artery disease warrants further investigation.
SUPPORTING INFORMATION
Additional Supporting Information may be found online in the supporting information tab for this article: Fig. S1 . CONSORT diagram showing the flow of participants through each stage of the randomized trial. Fig. S2 . Differences in the linear relationship between plasma 18-HEPE and urinary 20-HETE when drinking RW (closed triangles), DRW (closed squares), or water (closed circles) obtained from a linear mixed model. Table S1 . Urine and plasma 20-HETE, plasma EETs and DHETs, urine and plasma F 2 -isoprostanes and plasma SPM (18-HEPE, RvD1and 17R-RvD1) after 4 weeks of water, dealcoholized red wine (DRW) and red wine (RW). Table S2 . Linear mixed model showing the coefficients for the effect of urinary 20-HETE and each beverage on plasma 18-HEPE, adjusting for plasma 18-HEPE at baseline.
